Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

Apolipoprotein A-IV Stabilizes Glucose Metabolism in Diabetic Mouse Model

By BiotechDaily International staff writers
Posted on 04 Jun 2012
Print article
Apolipoprotein A-IV (apoA-IV), a protein manufactured by the small intestine during the digestive process, has been found to improve the ability of diabetic mice to control their glucose levels.

Investigators at the University of Cincinnati (OH, USA) worked with cultures of isolated pancreatic cells, with mice that had been genetically engineered to lack the gene for apoA-IV, and with KKAy diabetic mice.

They reported in the May 22, 2012, online edition of the journal Proceedings of the National Academy of Sciences of the USA that apoA-IV-treated isolated pancreatic islets had enhanced insulin secretion under conditions of high glucose but not of low glucose, suggesting a direct effect of apoA-IV to enhance glucose-stimulated insulin release. This enhancement involved cAMP (3'-5'-cyclic adenosine monophosphate) at a location distant from the point entry of calcium ions into insulin-producing beta cells.

Genetically engineered “knockout” of apoA-IV resulted in compromised insulin secretion and impaired glucose tolerance compared with wild type mice. Challenging mice lacking apoAI-V with a high-fat diet led to fasting hyperglycemia and more severe glucose intolerance associated with defective insulin secretion than occurred in wild type mice. Administration of exogenous apoA-IV to the “knockout” mice improved glucose tolerance by enhancing insulin secretion in mice fed either chow or a high-fat diet.

Injection of exogenous apoA-IV decreased blood glucose levels and stimulated a transient increase in insulin secretion in KKAy diabetic mice.

Senior author Dr. Patrick Tso, professor of pathology and laboratory medicine at the University of Cincinnati, said, “ApoA-IV behaves similar to an incretin - a gastrointestinal hormone causing an increased release of insulin after eating to combat the onset of elevated blood glucose. Two well-known incretins that have been used in the development of existing diabetes medications include gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1).”

"The problem with both of these incretins is that they are short-lived - lasting only for minutes - and are quickly inactivated by an enzyme,” said Dr. Tso. “They have also been linked to hypoglycemia, or low blood sugar, when administered when the body has a low glucose concentration. The challenge is to find something safer with a longer half-life.”

With its long (seven to eight hour) half-life apoA-IV may be a suitable therapeutic target for the regulation of glucose-stimulated insulin secretion and treatment of diabetes.

Related Links:
University of Cincinnati



Print article

Channels

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.